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Background: Osteoarthritis is a common chronic disease affecting aged populations. 
Conventional therapies tend to result in side effects when used long-term. Arthro-7® (Robinson 
Pharma, Orange County, CA, USA) has been used by osteoarthritis patients for more than 10 
years in the USA and has showed promising effects at relieving osteoarthritis-related symptoms. 
A previous small, double-blind study has shown some positive effects of Arthro-7 in reliev-
ing symptoms of osteoarthritis. The current study was performed specifically in osteoarthritis 
patients with mild to moderate arthralgia.
Methods: A total of 100 subjects over the age of 50 years old who were diagnosed with osteoar-
thritis and had at least one of the related symptoms were recruited to the study. After primary 
evaluation, 64 eligible males and females with mild or moderate degrees of arthralgia were 
randomly assigned 12-week treatment with either Arthro-7 or placebo. The primary outcome 
measurement was changes in the scores of the related symptoms before and after treatment, 
using the modified Western Ontario and McMaster Universities Arthritis Index (WOMAC) 
3.1 questionnaire. Prior to and at the end of the study, evaluations of symptom scores were 
recorded. Additionally, self-reported overall changes were recorded at the end of 2, 4, and 
8 weeks of treatment and at the end of the study (12 weeks).
Results: Arthro-7 improved most symptoms significantly compared with placebo, as indicated 
by significant reductions in symptom scores. In the Arthro-7 group, 74.5% of the participants 
reported symptom improvement over the study period versus only 16.3% in the placebo group.
Conclusion: In this study, Arthro-7 has shown potent effects in improving and relieving 
osteoarthritis-related symptoms, particularly joint pain, anchylosis, and difficulty going down 
stairs.
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Introduction
Osteoarthritis is a common chronic and degenerative osteoarthropathy,1–3 characterized 
by primary or secondary degeneration of the articular cartilage with hyperplasia of the 
bone under the cartilage.4–6 The main clinical manifestations are chronic arthralgia, 
anchylosis, and arthroncus with functional disorder. The disease generally involves 
the knees, spine, and interphalangeal joints. Arthritis affects nearly 50 million people 
in the USA,7 with prevalence rising as the population ages.8
Currently, analgesics and nonsteroidal anti-inflammatory drugs (NSAIDs) are 
the routine therapies for osteoarthritis. However, prolonged administration of these 
medications may cause side effects and complications.9
Arthro-7® (Robinson Pharma, Orange County, CA, USA) is a nutritional supple-
ment that has been marketed in the USA for more than a decade for the potential relief 
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of the symptoms of osteoarthritis, especially arthralgia, with 
no significant adverse effects reported so far. A previous 
study showed that Arthro-7 noticeably benefits osteoarthritis 
patients, especially in terms of pain relief.10 However, that 
study was undertaken mainly in patients with severe osteoar-
thritis. The current study, also a randomized, double-blind, 
controlled study in Chinese population, examined osteoarthri-
tis patients with only mild to moderate arthralgia. In addition, 
we also tested a different dose regimen, with patients using a 
high dose for the first 4 weeks, before switching to a mainte-
nance dose for the remaining 8 weeks of the study.
Methods
Materials
The Arthro-7 and placebo capsules were provided by 
Robinson Pharma (Orange County, CA, USA). The Arthro-7 
was in the form of soft gels containing vitamin C, collagen 
(from chicken) cetyl myristoleate (CMO), lipase, methylsul-
fonylmethane (MSM), curcumin, and bromelain (Table 1). 
The main ingredient of the placebo softgel was corn oil. In 
addition, there were gelatin, glycerin, purified water and 
titanium dioxide, and artificial food coloring.
Subjects
A total of 100 subjects (51 males and 49 females) over the age 
of 50 years old who were diagnosed with osteoarthritis11 and 
had at least one of the related symptoms (arthralgia, anchy-
losis, arthroncus, a walking problem, difficulty getting up 
from bed, or difficulty going down stairs) were recruited from 
the outpatient department of the community health service 
center of Tangqiao in Shanghai, China, in November 2011. 
The study excluded patients also suffering from cancer, 
calculus, a gastric ulcer, or gout, as well as those who had 
been using anti-inflammatory drugs, bromelain, antibiot-
ics, or antiplatelet agents. All potential participants met the 
symptomatic diagnostic standards of the American College of 
Rheumatology, based on physical and X-ray examinations.12 
All potential participants were screened by physical exami-
nation for arthralgia. Degree of arthralgia was determined 
as being between 0 and 4, as measured using the modified 
Western Ontario and McMaster Universities Arthritis Index 
(WOMAC) 3.1, where 0 indicates the absence of arthralgia 
and 4 indicates severe arthralgia.13 The WOMAC Index is a 
standardized questionnaire widely used by health profession-
als to evaluate the condition of patients with osteoarthritis.14,15 
According to our study design, only 64 subjects (31 males 
and 33 females) with mild or moderate arthralgia – that 
is, arthralgia with a WOMAC Index score # 2 – were eligible 
to participate in this study. All participants provided written, 
informed consent prior to participating.
Intervention
Each of the 64 eligible participants was randomly assigned to 
the “Arthro-7 group” or the “placebo group” at a ratio of 1:2. 
Patients in the Arthro-7 group received two capsules of 
Arthro-7 orally twice per day for the first 4 weeks, followed 
by two capsules once per day from week 5 to week 12. 
We were interested in the immediate short-term effect of 
Arthro-7 at a high dose level, followed by a maintenance 
dose, thus a dose-change regimen was used at 4 weeks after 
the initial high dose intervention. Meanwhile, patients in the 
placebo group received a similar-looking bottle of capsules 
(the only difference was the color of the bottle cap [the 
treatment bottle had a white cap and the placebo bottle had 
a yellow cap, but this was blinded for both study subjects 
and researchers]) and took these at the same frequency. The 
total intervention period lasted for 12 weeks. All participants 
were followed up every 2 weeks in the first month of inter-
vention, and once per month for the following 2 months. 
Medications were dispensed with follow-ups. All follow-
ups for both the Arthro-7 group and placebo group were 
completed. There were no losses to follow-up until the end 
of the intervention.
Assessment of outcomes
The objective of the study was to determine whether daily 
use of Arthro-7 would relieve symptoms of osteoarthritis 
(arthralgia, anchylosis, arthroncus, any walking problem, 
difficulty getting up from bed, and difficulty descending 
stairs) in the designed populations.
At baseline and the end of the intervention period, doctors 
gave scores for the symptoms mentioned for every partici-
pant, determined by physical examination, ranging from 0 
to 4, with 0 indicating the absence of a given symptom and 
4 indicating a severe degree of the symptom. The age, sex, 
history of alcohol consumption, and medical and medication 
history of all participants were also collected at baseline.
Table 1 Major ingredients of Arthro-7®
Vitamin C
Collagen (from chicken)
Cetyl myristoleate
Lipase
Methylsulfonylmethane
Curcumin
Bromelain
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Along with follow-up, self-reported side effects and 
adherences were recorded.
Statistical analysis
Variables were compared between the two groups using 
Student’s t-test for interval variables and either the Chi-
square or Fisher’s exact test for nominal variables. Paired 
t-test was applied to compare the symptom scores before and 
after the intervention. Simple linear regression was used to 
estimate the difference of score reduction between the two 
groups. Stata/MP (v 11.2; Statacorp, College Station, TX, 
USA) was used for all statistical analyses. The alpha level 
we chose was 0.05. Analyses were conducted using intent-
to-treat analysis. All P-values presented are two-sided.
Results
Of the 64 eligible participants who underwent randomization 
at the ratio of 1:2, 22 were assigned to the Arthro-7 group 
and 42 to the placebo group, with no losses to follow-up until 
the end of the study. There was no significant difference in 
adherence between the two groups.
Baseline data
The baseline characteristics of the two groups were com-
patible in terms of age, sex, history of alcohol consump-
tion, and whether the participants had “used osteoarthritis 
drugs recently (including herbs and OTC [over the counter] 
drugs).”
Baseline symptom scores were also compatible for most 
osteoarthritis symptoms (arthralgia, anchylosis, arthroncus, 
difficulty getting up from bed and difficulty descending 
stairs). The only exception was for walking problems, for 
which the mean scores were 0.50 and 0.07 for the Arthro-7 
and placebo groups, respectively (P = 0.0012). Generally, 
the two arms were well balanced at baseline due to random-
ization (Table 2).
Results after intervention
After 12 weeks, all six symptoms of study focus were 
  reassessed. Table 3 displays the score for each item and dis-
tribution of each symptom in the two groups. The individual 
score for arthralgia was statistically different between the 
two arms (Table 3).
Paired t-test comparing the symptom scores before and 
after the intervention showed that, except for difficulty in 
getting up from bed, all other symptoms were relieved by 
Arthro-7 treatment. The same kinds of change were not 
observed in the placebo group (Table 4).
To reveal detailed associations, the individual score 
reductions, specific to every symptom of interest for each 
participant, were calculated. Linear regression was conducted 
to estimate the differences in the symptom-specific score 
reduction between the two groups. Additional score reduc-
tions resulting from Arthro-7 use, compared with placebo; the 
statistical significance of the differences; and 95% confidence 
intervals for the estimates are given in Table 5.
Almost all the symptoms (the only exception was dif-
ficulty getting up from bed), as shown in Table 5, were 
significantly relieved as a result of Arthro-7 treatment. For 
example, we found that the symptom score for arthralgia 
would decrease 0.911 points more, on average, in the 
Arthro-7 group than in the placebo group. Other parameters 
in Table 5 can be interpreted analogously.
The self-reported overall symptom improvement dur-
ing the study period suggests that Arthro-7 has potent 
effects. After 2 weeks of intervention, 39.2% of participants 
Table 2 Baseline characteristics
Characteristic‡  Arthro-7 (n = 22) Placebo (n = 42) Total (n = 64)
Sex, n
  Male 9 22 31
  Female 13 20 33
Age, y (±SD) 66.21 ± 7.04 66.08 ± 11.15
History of alcohol consumption, n (%) 4 (18.2) 14 (33.3)
Used osteoarthritis drugs recently, (%) 12 (54.5) 13 (31.0)
Arthralgia, mean ± SD 1.77 ± 0.528 1.74 ± 0.445
Anchylosis, mean ± SD 1.00 ± 0.816 0.69 ± 0.643
Arthroncus, mean ± SD 0.18 ± 0.395 0.10 ± 0.297
Walking problem*, mean ± SD 0.50 ± 0.673 0.07 ± 0.342
Difficulty in getting up from bed, mean ± SD 0.14 ± 0.468 0.07 ± 0.261
Difficulty descending stairs, mean ± SD 1.00 ± 0.873 0.69 ± 0.680
Notes: ‡Symptom scores ranged from 0 to 4, using the modified WOMAC® 3.1 questionnaire; *statistically significant difference, P = 0.0012 (Student’s t-test).
Abbreviation: SD, standard deviation.
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in the Arthro-7 group reported overall symptom relief, 
compared with none in the placebo group. At the end of 
the first month of intervention, 45.1% of participants in the 
Arthro-7 group reported symptom improvement. Four weeks 
later, 60.8% of participants in the Arthro-7 group reported 
symptom improvement. At the end of the study, about three-
quarters of participants in the Arthro-7 group reported overall 
symptom relief, compared with only 16.3% in the placebo 
group (Table 6).
Discussion
Osteoarthritis is a common chronic disease affecting major 
segments of the population who are over middle age.16 
Routine therapies, such as NSAIDs, for osteoarthritis are 
useful, but can also lead to adverse effects and complications 
over long-term administration.17 This study was designed 
as a double-blind, randomized, controlled trial to determine 
whether daily administration of the alternative dietary supple-
ment, Arthro-7, could relieve symptoms in osteoarthritis 
patients with mild to moderate arthralgia.
As previously outlined, Arthro-7 is composed of a mixture 
of ingredients including vitamin C, collagen (from chicken), 
CMO, lipase, MSM, curcumin, and bromelain (Table 1). 
Collagen – the main component of articular cartilage and the 
principal substance responsible for maintaining the physical, 
chemical, and mechanical properties of articular cartilage – 
accounts for about 85% to 90% of the Arthro-7. The collagen 
(from chicken) (CC) in Arthro-7 is extracted from chicken 
breast bone, which has previously been shown to suppress 
collagen-induced arthritis.18 In that study, Garcia et al showed 
that CC could suppress the body’s autoimmune response 
and postpone the degradation of cartilage by inducing 
immuno-tolerance.18 In another study, patients diagnosed 
with rheumatoid arthritis treated with CC showed pronounced 
improvement of their disease symptoms.19 These results may 
be attributed to the similarity between osteoarthritis and 
rheumatoid arthritis in terms of pathogenesis and pathologi-
cal changes, such as the induction of autoimmune responses, 
arthromeningitis, and over destruction of the articular carti-
lage. Using rat models of osteoarthritis, some studies have 
found that CC may correct the imbalance between cartilage 
matrix-degrading enzymes and the enzymes inhibitors, thus 
delaying the degradation of cartilage.20 Other individual 
components in Arthro-7 such as MSM, lipase, bromelain, 
curcumin, and vitamin C have been individually shown to 
help relieve symptoms of osteoarthritis.21,22
Table 3 Symptom scores after intervention
Symptom‡ Arthro-7®, mean ± SD Placebo, mean ± SD t-statistic P
Arthralgia* 0.91 ± 0.750 1.79 ± 0.717 4.5733 ,0.0001
Anchylosis 0.50 ± 0.598 0.74 ± 0.701 1.3555 0.1802
Arthroncus 0.00 ± 0.000 0.10 ± 0.297 1.4978 0.1393
Walking problem 0.23 ± 0.528 0.07 ± 0.342 −1.4288 0.1581
Difficulty in getting up from bed 0.09 ± 0.294 0.07 ± 0.261 −0.2716 0.7868
Difficulty descending stairs 0.45 ± 0.596 0.74 ± 0.885 1.3486 0.1824
Notes: ‡Symptom scores ranged from 0 to 4, using the modified WOMAC® 3.1 questionnaire; *statistically significant difference, P , 0.05 (Student’s t-test).
Abbreviation: SD, standard deviation.
Table 5 Comparison of individual changes between the two 
groups
Symptom† Score reduction  
difference‡
P 95% CI
Arthralgia 0.911 ,0.001 0.594 to 1.228
Anchylosis 0.548 ,0.001 0.303 to 0.792
Arthroncus 0.182 0.004 0.061 to 0.303
Walking problem 0.273 ,0.001 0.133 to 0.412
Difficulty in getting  
up from bed
0.045 0.169 −0.020 to 0.111
Difficulty descending  
stairs
0.593 0.001 0.257 to 0.930
Notes: †Symptom scores ranged from 0 to 4, using the modified WOMAC® 3.1 
questionnaire; ‡linear regression was applied in comparing the differences of score 
reduction between the two intervention groups.
Abbreviation: CI, confidence interval.
Table 4 Comparison of symptom scores before and after the 
intervention
Symptom† Arthro-7® Placebo
t-statistic‡ P t-statistic‡ P
Arthralgia 5.7041 ,0.0001 −0.5727 0.5700
Anchylosis 3.4868 0.0022 −1.0000 0.3232
Arthroncus 2.1602 0.0425 – –
Walking problem 2.8062 0.0106 – –
Difficulty in getting  
up from bed
1.0000 0.3287 – –
Difficulty descending  
stairs
2.9823 0.0071 −0.6279 0.5336
Notes: †Symptom scores ranged from 0 to 4, using the modified WOMAC® 3.1 
questionnaire; ‡paired t-test was applied to compare the symptom scores before 
and after the intervention. Some of the of the t-statistics could not be performed 
because the standard error of the difference was 0.
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This study showed that Arthro-7 could remarkably allevi-
ate joint pain in osteoarthritis patients. As mentioned in the 
results section, after a 12-week intervention, five of the six 
symptoms this study focused on were significantly relieved 
by Arthro-7 and the mean arthralgia scores were found to 
decrease by 0.911 points more in the Arthro-7 group than in 
the placebo group. Moreover, 74.5% of participants in the 
Arthro-7 group had experienced overall symptom relief by the 
end of the study period (12 weeks), compared with ,20% in 
the placebo group. Together, these findings strongly indicate 
that Arthro-7 is very effective at relieving osteoarthritis-
related symptoms.
Further, in this study, Arthro-7 was very effective at 
relieving anchylosis and improving the ability of osteoar-
thritis patients to descend stairs. The use of Arthro-7 was 
found to cause a reduction of 0.548 and 0.593 points more 
than taking the placebo for the symptoms of anchylosis and 
difficulty descending stairs, respectively.
Arthro-7 also showed statistically significant effects at 
relieving arthroncus and improving walking difficulties, 
although the magnitudes were considerably limited (a reduc-
tion of 0.182 and 0.273 points, respectively).
For difficulty getting up from bed, the difference between 
the two groups was very limited. There was insufficient 
evidence to distinguish the effects of Arthro-7 from placebo 
for this symptom.
In this study, the effect estimates of Arthro-7 were 
investigated in terms of individual level of magnitude and 
overall improvement rate, as we believe both aspects are 
equally important in decision-making. Combining these two 
aspects, especially when they are consistent, could enhance 
our confidence of determination of the effect  of Arthro-7 in 
relieving symptoms of OS.
As in many randomized, controlled studies, we followed 
intent-to-treat policy, ignoring nonadherence. Subjects 
were compared based on initial randomization intervention 
groups. This method allowed us to avoid potential biases in 
comparison based on per-protocol analysis, since there was 
no evidence to suppose nonadherence was randomly distrib-
uted, though this method might lead to underestimation of 
the effect size.
Limitations
There were several limitations in this study. First, objective 
indicators such as blood samples, which can monitor the 
changes in cytokines associated with inflammatory responses, 
were not collected during the study period. The addition of 
these measurements to future studies may aid in determina-
tion of the mechanisms responsible for the anti-inflammatory 
effect of Arthro-7.
Second, since the study tested Arthro-7 as a single agent, 
it is not possible to attribute the effect to a specific ingredi-
ent of the compound, as the study only tested Arthro-7 as 
an existing single nutritional supplement, not the individual 
ingredients within it.
Third, although bromelain, antibiotics, or antiplatelet/
anti-inflammatory agent (eg, NSAID) takers were excluded, 
there were still some potential confounding factors, such 
as weight, lifestyle, diet, and other drugs or supplements, 
that were not controlled for in our study. However, as the 
two groups were well balanced at baseline, we decided that 
the effects of differences in dietary intake or other potential 
confounding factors would be minimal.
Moreover, the results are only applicable to the sample 
range in this study, and should not be generalized to popula-
tions outside the sample range, as there may be a generalizing 
problem. Further study is therefore needed to confirm whether 
Arthro-7 is similarly efficacious in other populations.
Another limitation of the study was the use of a ques-
tionnaire to collect baseline information, as this relied on 
participants’ recall. Thus, the results from this part may be 
prone to recall bias.
Finally, all our participants were volunteers; any eligible 
persons who did not wish to participate were excluded. If 
those who were excluded were not exactly compatible with 
those enrolled for the study, the results would suffer a selec-
tion bias.
Conclusion
In summary, our study showed that Arthro-7 has potent 
effects at relieving joint pain, anchylosis, and improving 
difficulty descending stairs in osteoarthritis patients. The 
effects on arthroncus and walking difficulties were limited, 
but statistically significant. These factors and results may 
assist physicians in determining Arthro-7’s clinical applica-
tions and significance.
Disclosure
Mina Shariff, Kenneth Kami, and Pingping Gu are current or 
previous employees of DRM Resources, which sponsored this 
Table 6 Self-reported symptom improvement over the study 
period (%)
2 weeks 4 weeks 8 weeks 12 weeks
Arthro-7® 39.2 45.1 60.8 74.5
Placebo 0.0 4.1 6.1 16.3
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project. The supplier of the Arthro-7 and placebo capsules, 
Robinson Pharma, had no role in the design or conduction 
of the study; the collection, management, analysis and 
  interpretation of the data; or the preparation, review, and 
approval of this paper for publication. The other authors have 
no conflicts of interest in this work.
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